» Articles » PMID: 39114410

No More Government-imposed Societal-level COVID-19 Control Measures but Still Significant Self-experienced Burden for Severely Immunocompromised Individuals - A Cross-sectional Survey in the Netherlands

Overview
Journal Prev Med Rep
Date 2024 Aug 8
PMID 39114410
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: In March 2023, all societal-level COVID-19 control measures were lifted by the Dutch government. This study was performed to understand the self-experienced burden of this new phase of COVID-19 on the perspectives and behaviors of severely immunocompromised individuals.

Methods: This is an observational, descriptive, cross-sectional study in The Netherlands. An online survey was completed by severely immunocompromised individuals, to capture their general well-being (score from 1 = worst to 10 = best), mental and physical health, and daily and social activities during survey conduct and retrospectively for before onset of COVID-19. The survey was open for completion from May 24th until August 7nd, 2023.

Results: Of the 236 respondents, 96.6 % had been vaccinated against COVID-19 and 24.6 % were shielding to avoid COVID-19 during survey conduct. The general well-being score for all respondents was 7.5 (±1.2 SD) before onset of the COVID-19 pandemic and 6.9 (±1.6 SD) during survey conduct (P<0.001). For the shielding group (n = 58), these scores were 7.6 (±1.0 SD) and 5.7 (±1.6 SD), respectively (P<0.001). Generally, for all questions about mental and physical health and daily and social activities, there was a trend towards more negative answers during survey conduct, compared with before onset of the COVID-19 pandemic, which was more pronounced for the shielding group.

Conclusions: Despite absence of government-imposed societal measures, COVID-19 avoidance still had a self-experienced burden on perspectives and behaviors of immunocompromised individuals in The Netherlands, with a significantly lower general well-being during survey conduct, compared with before onset of COVID-19.

Citing Articles

Life after Lockdown: An Exploratory Qualitative Study of Behaviors and Impacts of Avoiding COVID-19 in Individuals at High Risk of Severe COVID-19 and Their Caregivers.

Maia T, Yokota R, Arnetorp S, Smith J, Rae-Garwood G, Settergren G Int J Environ Res Public Health. 2024; 21(10).

PMID: 39457280 PMC: 11507298. DOI: 10.3390/ijerph21101307.

References
1.
Jassat W, Abdool Karim S, Mudara C, Welch R, Ozougwu L, Groome M . Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study. Lancet Glob Health. 2022; 10(7):e961-e969. PMC: 9116895. DOI: 10.1016/S2214-109X(22)00114-0. View

2.
Evans R, Dube S, Lu Y, Yates M, Arnetorp S, Barnes E . Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study. Lancet Reg Health Eur. 2023; 35:100747. PMC: 10730312. DOI: 10.1016/j.lanepe.2023.100747. View

3.
Westcott K, Wilkins F, Chancellor A, Anderson A, Doe S, Echevarria C . The impact of COVID-19 shielding on the wellbeing, mental health and treatment adherence of adults with cystic fibrosis. Future Healthc J. 2021; 8(1):e47-e49. PMC: 8004337. DOI: 10.7861/fhj.2020-0205. View

4.
Lee A, Wong S, Chai L, Lee S, Lee M, Muthiah M . Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022; 376:e068632. PMC: 8889026. DOI: 10.1136/bmj-2021-068632. View

5.
Tartof S, Slezak J, Puzniak L, Hong V, Xie F, Ackerson B . Immunocompromise and durability of BNT162b2 vaccine against severe outcomes due to omicron and delta variants. Lancet Respir Med. 2022; 10(7):e61-e62. PMC: 9075856. DOI: 10.1016/S2213-2600(22)00170-9. View